{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Identification of novel therapy-responsive protein biomarkers for Duchenne muscular dystrophy by aptamer-based serum proteomics\n

\n \n \n \n \n\n \n \n \n

Coenen-Stass A. et al, (2015), NEUROMUSCULAR DISORDERS, 25, S251 - S252

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides.\n

\n \n \n \n \n\n \n \n \n

Hammond SM. et al, (2014), Mol Ther Nucleic Acids, 3

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Design and application of bispecific splice-switching oligonucleotides.\n

\n \n \n \n \n\n \n \n \n

Bestas B. et al, (2014), Nucleic Acid Ther, 24, 13 - 24

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides.\n

\n \n \n \n \n\n \n \n \n

Hammond SM. et al, (2014), Mol Ther Nucleic Acids, 3

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover.\n

\n \n \n \n \n\n \n \n \n

Roberts TC. et al, (2013), Nucleic Acids Res, 41, 9500 - 9513

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.\n

\n \n \n \n \n\n \n \n \n

Malerba A. et al, (2012), Mol Ther Nucleic Acids, 1

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy.\n

\n \n \n \n \n\n \n \n \n

Roberts TC. et al, (2012), Mol Ther Nucleic Acids, 1

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Small RNA-Mediated Epigenetic Myostatin Silencing.\n

\n \n \n \n \n\n \n \n \n

Roberts TC. et al, (2012), Mol Ther Nucleic Acids, 1

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD\n

\n \n \n \n \n\n \n \n \n

Godfrey C. et al, (2012), NEUROMUSCULAR DISORDERS, 22, S8 - S8

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Antisense oligonucleotide corrects splice abnormality in hereditary myopathy with lactic acidosis.\n

\n \n \n \n \n\n \n \n \n

Sanaker PS. et al, (2012), Gene, 494, 231 - 236

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Antisense oligonucleotide corrects splice abnormality in hereditary myopathy with lactic acidosis\n

\n \n \n \n \n\n \n \n \n

(2012), Gene, 494, 231 - 236

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy.\n

\n \n \n \n \n\n \n \n \n

Roberts TC. et al, (2012), Mol Ther Nucleic Acids, 1

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n LEPIGENETIC MYOSTATIN BLOCKADE\n

\n \n \n \n \n\n \n \n \n

Roberts T. et al, (2011), NUCLEIC ACID THERAPEUTICS, 21, A24 - A24

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Antisense oligonucleotide correction of splice error in cultured ISCU myopathy muscle cells\n

\n \n \n \n \n\n \n \n \n

Sanaker PS. et al, (2010), NEUROMUSCULAR DISORDERS, 20, 676 - 676

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Allele-specific RNA interference to target a model of slow-channel congenital myasthenic syndrome\n

\n \n \n \n \n\n \n \n \n

McClorey G. et al, (2008), NEUROMUSCULAR DISORDERS, 18, 749 - 749

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.\n

\n \n \n \n \n\n \n \n \n

Moulton HM. et al, (2007), Biochem Soc Trans, 35, 826 - 828

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript.\n

\n \n \n \n \n\n \n \n \n

Wilton SD. et al, (2007), Mol Ther, 15, 1288 - 1296

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n A personalised genetic treatment for DMD\n

\n \n \n \n \n\n \n \n \n

Fletcher S. et al, (2007), JOURNAL OF GENE MEDICINE, 9, 529 - 529

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript\n

\n \n \n \n \n\n \n \n \n

Wilton SD. et al, (2007), JOURNAL OF GENE MEDICINE, 9, 534 - 534

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Induced dystrophin exon skipping in human muscle explants\n

\n \n \n \n \n\n \n \n \n

Adams AM. et al, (2007), JOURNAL OF GENE MEDICINE, 9, 534 - 535

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }